UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma

Scientific reports, 2022-08, Vol.12 (1), p.14439-14439, Article 14439

2022

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab for the Treatment of Glioblastoma

Clinical Medicine Insights. Oncology, 2013-01, Vol.2013 (7), p.123-135

2013

Link zum Volltext

Verfügbarkeit prüfen

Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker

Cells (Basel, Switzerland), 2023-03, Vol.12 (6), p.843

2023

Link zum Volltext

Verfügbarkeit prüfen

Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: Final results of a phase II study

Lung cancer (Amsterdam, Netherlands), 2008-10, Vol.62 (1), p.62-71

2008

Link zum Volltext

Verfügbarkeit prüfen

Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age

Journal of neuro-oncology, 2019-07, Vol.143 (3), p.515-523

2019

Link zum Volltext

Verfügbarkeit prüfen

Gene fusions in glioblastoma: Results of Gliocat project

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2042-2042

2021

Link zum Volltext

Verfügbarkeit prüfen

Is IDO1 an adequate target for treatment in glioblastoma?

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e14039-e14039

2022

Link zum Volltext

Verfügbarkeit prüfen

CTNI-54. A COMBINED ANALYSIS OF TWO RANDOMISED STUDIES EXPLORING THE IMPACT OF EXTENDED POST-RADIATION TEMOZOLOMIDE ON SURVIVAL OUTCOMES IN NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v88-v88

2023

Link zum Volltext

Verfügbarkeit prüfen

Long-term results of the GEINO 1401 TRIAL: Randomizing patients to stop or to continue temozolomide until 12 cycles

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2013-2013

2021

Link zum Volltext

Verfügbarkeit prüfen

P3-061: Erlotinib as single agent in elderly patients (p) with advanced or metastatic NSCLC

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S703-S704

2007

Link zum Volltext

Verfügbarkeit prüfen

Pseudoprogression as an adverse event of glioblastoma therapy

Cancer medicine (Malden, MA), 2017-12, Vol.6 (12), p.2858-2866

2017

Link zum Volltext

Verfügbarkeit prüfen

Galectin-1 (Gal-1) expression as a prognostic factor in patients with newly diagnosed glioblastoma (GB) treated with Stupp regimen (GLIOCAT study)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e13526-e13526

2017

Link zum Volltext

Verfügbarkeit prüfen

Feasibilty study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function

Clinical & translational oncology, 2006-10, Vol.8 (10), p.755-757

2006

Link zum Volltext

Verfügbarkeit prüfen

Gene expression profiling of glioblastoma (GBM) in an homogeneous treated population: Correlation with immunohistochemistry, radiology, clinical outcome, and response to therapy—A multicenter study from the GLIOCAT group, Marato TV3 2012, project 665/c/2013

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e13515-e13515

2016

Link zum Volltext

Verfügbarkeit prüfen

Feasibility and efficacy of concomitant chemoradiation (Ch-RT) in the management of newly diagnosed elderly glioblastoma (GB) patients: Results from the GLIOCAT study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2045-2045

2016

Link zum Volltext

Verfügbarkeit prüfen

Long-term survivors in glioblastoma patients homogeneously treated with the Stupp regimen, clinical characteristics and MGMT status: Initial results from the GLIOCAT study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e13513-e13513

2016

Link zum Volltext

Verfügbarkeit prüfen

ACTR-48. AN APPRAISAL OF THE IMPACT ON SURVIVAL OF NEOADJUVANT TREATMENTS DELAYING RADIOTHERAPY IN ‘ONLY-BIOPSIED GLIOBLASTOMA’ TRIALS CONDUCTED BY THE GEINO GROUP COMPARED TO PATIENTS TREATED WITH THE STUPP’S REGIME. EXPERIENCE OF THE GEINO AND THE GLIOCAT GROUP

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi11-vi11

2017

Link zum Volltext

Verfügbarkeit prüfen

Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function

Clinical & translational oncology, 2006-10, Vol.8 (10), p.755

2006

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice

Breast cancer research and treatment, 2012-08, Vol.134 (3), p.1161-1168

2012

Link zum Volltext

Verfügbarkeit prüfen

MRI contrast enhancement (CE): Analysis as survival prognostic factor in low grade gliomas (LGG)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e14031-e14031

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(55)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Life Sciences & Biomedicine
(20)
Humans
(17)
Oncology
(16)
Female
(13)
Middle Aged
(12)
Male
(11)
Aged
(10)
Adult
(8)
Chemotherapy
(8)
Tumors
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Glioblastoma
(6)
Prognosis
(5)
Cancer
(4)
Head And Neck Neoplasms - Pathology
(4)
Multidisciplinary Sciences
(4)
Science & Technology - Other Topics
(4)
Squamous Cell Carcinoma
(4)
Toxicity
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)

In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma

Bevacizumab for the Treatment of Glioblastoma

Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker

Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: Final results of a phase II study

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age

Gene fusions in glioblastoma: Results of Gliocat project

Is IDO1 an adequate target for treatment in glioblastoma?

CTNI-54. A COMBINED ANALYSIS OF TWO RANDOMISED STUDIES EXPLORING THE IMPACT OF EXTENDED POST-RADIATION TEMOZOLOMIDE ON SURVIVAL OUTCOMES IN NEWLY DIAGNOSED GLIOBLASTOMA

Long-term results of the GEINO 1401 TRIAL: Randomizing patients to stop or to continue temozolomide until 12 cycles

Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy

RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma

P3-061: Erlotinib as single agent in elderly patients (p) with advanced or metastatic NSCLC

Pseudoprogression as an adverse event of glioblastoma therapy

Galectin-1 (Gal-1) expression as a prognostic factor in patients with newly diagnosed glioblastoma (GB) treated with Stupp regimen (GLIOCAT study)

Feasibilty study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function

Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)

Gene expression profiling of glioblastoma (GBM) in an homogeneous treated population: Correlation with immunohistochemistry, radiology, clinical outcome, and response to therapy—A multicenter study from the GLIOCAT group, Marato TV3 2012, project 665/c/2013

Feasibility and efficacy of concomitant chemoradiation (Ch-RT) in the management of newly diagnosed elderly glioblastoma (GB) patients: Results from the GLIOCAT study

Long-term survivors in glioblastoma patients homogeneously treated with the Stupp regimen, clinical characteristics and MGMT status: Initial results from the GLIOCAT study

ACTR-48. AN APPRAISAL OF THE IMPACT ON SURVIVAL OF NEOADJUVANT TREATMENTS DELAYING RADIOTHERAPY IN ‘ONLY-BIOPSIED GLIOBLASTOMA’ TRIALS CONDUCTED BY THE GEINO GROUP COMPARED TO PATIENTS TREATED WITH THE STUPP’S REGIME. EXPERIENCE OF THE GEINO AND THE GLIOCAT GROUP

Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function

Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice

MRI contrast enhancement (CE): Analysis as survival prognostic factor in low grade gliomas (LGG)

Suchergebnisse filtern